Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 40% Improvement Relative Risk Hospitalization time -30% c19early.org/cp Pouladzadeh et al. IRCT20200310046736N1 Conv. Plasma RCT LATE Favors conv. plasma Favors control
A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm
Pouladzadeh et al., Internal and Emergency Medicine, doi:10.1007/s11739-021-02734-8, IRCT20200310046736N1
Pouladzadeh et al., A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related.., Internal and Emergency Medicine, doi:10.1007/s11739-021-02734-8, IRCT20200310046736N1
Apr 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 62 hospitalized patients in Iran, showing no significant difference in mortality and length of stay with convalescent plasma.
risk of death, 40.0% lower, RR 0.60, p = 0.71, treatment 3 of 30 (10.0%), control 5 of 30 (16.7%), NNT 15.
hospitalization time, 30.0% higher, relative time 1.30, p = 0.06, treatment 30, control 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pouladzadeh et al., 10 Apr 2021, Single Blind Randomized Controlled Trial, multiple countries, peer-reviewed, mean age 53.5, 17 authors, study period March 2020 - May 2020, trial IRCT20200310046736N1.
Contact: msafdaryan@gmail.com, parastoomoradi40@yahoo.com.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Abstract: Internal and Emergency Medicine (2021) 16:2181–2191 https://doi.org/10.1007/s11739-021-02734-8 IM - ORIGINAL A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID‑19‑related cytokine storm Mandana Pouladzadeh1 · Mehdi Safdarian2 · Peyman Eshghi3,4 · Hassan Abolghasemi5 · Alireza Ghorbani bavani6 · Behnam Sheibani7 · Parastoo Moradi Choghakabodi8 · Abdolaziz Feghhi9 · Mehri Ghafourian Boroujerdnia10 · Arash Forouzan11 · Mohammad Ali Jalali Far8 · Gholam Abbas Kaydani12 · Elham Rajaei13 · Mansour Amin14,15 · Mehdi Torabizadeh16 · Farid Yousefi15 · Reza Hadaddezfuli17 Received: 11 December 2020 / Accepted: 30 March 2021 / Published online: 10 April 2021 © Società Italiana di Medicina Interna (SIMI) 2021 Abstract Evaluating the effect of convalescent plasma (CP) on some cytokine storm indices in severe COVID-19 patients. Totally, 62 patients were randomly assigned into two groups for this clinical trial. Patients in the intervention group received one unit (500 mL) plasma on the admission day plus standard drugs while the controls merely received standard treatments. Eventually, primary and secondary outcomes were evaluated. In the CP group, compared with controls, the mean levels of lymphocytes and IL-10 significantly increased while the levels of IL-6, TNF-α, and IFN-γ decreased (p < 0.05). The length of in-hospital stay, and mortality rate did not significantly reduce in the CP group compared with controls (p > 0.05) while WHO severity scores remarkably improved (p = 0.01), despite the higher frequency of underlying diseases among the CP group (66.7%) vs. controls (33.3%). Although CP has a remarkable immunomodulatory and antiviral potential to improve the cytokine storm and disease severity in COVID-19 patients, it did not considerably affect the mortality rate. Keywords Convalescent plasma · COVID-19 · Cytokine storm
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit